EUCTR2009-017434-45-ES进行中（未招募）不适用
A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates with HyperbilirubinemiaEnsayo de fase 2b, multicéntrico, de dosis única, ciego, aleatorizado, controlado por placebo, con aumento escalonado de la dosis para comprobar la seguridad y la eficacia de la estansoporfina (Stanate®) en neonatos con hiperbilirrubinemia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Term and late preterm subjects (>=35 weeks and <43 weeks gestational age)
- •- Risk factors for hemolytic disease to include subjects with ABO blood type incompatibility or Rh incompatibility (anti-C, c, D, E, or e)
- •- A minimum birth weight of 2500 g (5.5 lbs)
- •- Coombs test results available
- •- Within 2 mg/dL below the threshold for PT per the AAP Guidelines (see Appendix A) at up to 12 hours of age or within 3 mg/dL below the threshold for PT at >12 to 48 hours of age, inclusive (see Appendix B)
- •- Willingness for parents/guardians to adhere to recommendations regarding light precautions
- •- Written informed consent obtained from parents/guardians
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Family history of glucose-6-phosphate dehydrogenase (G6PD) deficiency
- •- Clinical suggestion of neonatal thyroid disease or current uncontrolled thyroid disease in the mother (maternal Hashimoto´s disease is not exclusionary)
- •- Treatment or need for treatment in the neonate with medications that may prolong the QT interval (see Appendix C) (erythromycin ointment for eye prophylaxis is permitted), family history of Long QT syndrome or family history of Sudden Infant Death syndrome
- •- Known porphyrias or risk factors for porphyrias, including family history
- •- A maternal history of systemic lupus erythematosus
- •- Maternal use of phenobarbital 30 days before, or after delivery, if breastfeeding
- •- Maternal current drug or alcohol abuse, or maternal history of drug or alcohol abuse, that, in the opinion of the Investigator, would not make the subject a suitable candidate for participation in the clinical trial
- •- Apgar score =< 6 at age 5 minutes
- •- Significant congenital anomalies or infections
- •- Cardiorespiratory distress, defined as a respiratory rate >60 breaths per minute, at time of enrollment, unless a diagnosis of transient tachypnea of the newborn has been made
- •- Any abnormal auditory or ophthalmologic findings at Screening: Subjects who fail initial auditory screen may be rescreened
- •- Any excess risk of requiring surgery or exposure to operating room lights in the foreseeable future
- •- Clinically significant abnormalities on screening laboratory evaluation
- •- Elevated direct or conjugated bilirubin (>1.0 mg/dL if the TSB is <5.0 mg/dL or >20% of the TSB if the TSB is >= 5.0 mg/dL)
- •- Persistent hypoglycemia (blood glucose <40 mg/dL) despite standard-of-care treatment
- •- Alanine aminotransferase >2 times the upper limit of normal (ULN) or aspartate aminotransferase >3 times the ULN
- •- Abnormal renal function defined as creatinine and/or blood urea nitrogen >2 times the ULN
- •- Any blood smear finding of structural red cell abnormalities, such as spherocytosis, not caused by isoimmune hemolysis
- •- Temperature instability defined as temperature consistently (3 consecutive times) <36ºC and/or >37.5ºC axillary
- •- Use of photosensitizing drugs or agents (see Appendix D)
- •- Use of intravenous immunoglobulin (IVIG) or albumins
- •- Postdelivery treatment with medications that are known or suspected to displace bilirubin from albumin (eg, ceftriaxone or sulfa-based antibiotics)
- •- Other serious morbid conditions, eg, pulmonary disease, cardiovascular disease
- •- Exposure to any investigational medications or devices after delivery, or participation in another clinical trial while participating in this trial
- •- Any other concurrent medical condition that, in the opinion of the Investigator, makes the subject unsuitable for the clinical trial
- •- Unwillingness for parents/guardians to adhere to recommendations regarding light precautions
研究者
相似试验
Unknown
2 期
A clinical trial to study the effects of Stannsoporfin in neonates with hyperbilirubenemiaCTRI/2010/091/000490InfaCare Pharmaceutical Corporation, 8 Neshaminy Interplex, Suite 221Trevose, PA 19053-6944, USA72
进行中（未招募）
1 期
A controlled clinical trial to investigate the safety and effectiveness of Stannsoporfin in newborn children with excess amounts of bilirubin in the blood.eonatal hyperbilirubinemiaHiperbilirubinemia neonatalMedDRA version: 14.0Level: PTClassification code 10020580Term: Hyperbilirubinaemia neonatalSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2009-017434-45-PLInfaCare Pharmaceutical Corporation72
进行中（未招募）
1 期
A Phase 2B, Randomized, Multicenter, Dose-Ranging Study Assessingthe Safety and Efficacy of PD 0348292 in the Prevention of Venous ThromboembolicEvents (VTE) in Subjects Undergoing an Elective, Unilateral Total Knee Replacement - N/APrevention of Venous Thromboembolic EventsMedDRA version: 8.0Level: HLGTClassification code 10014523EUCTR2005-005179-14-DKPfizer Limited1,255
进行中（未招募）
1 期
A Phase 2B, Randomized, Multicenter, Dose-Ranging Study Assessingthe Safety and Efficacy of PD 0348292 in the Prevention of Venous ThromboembolicEvents (VTE) in Subjects Undergoing an Elective, Unilateral Total Knee ReplacementPrevention of Venous Thromboembolic EventsMedDRA version: 8.0Level: HLGTClassification code 10014523EUCTR2005-005179-14-ESPFIZER, S.A.1,255
进行中（未招募）
不适用
A Phase 2B, Randomized, Multicenter, Dose-Ranging Study Assessingthe Safety and Efficacy of PD 0348292 in the Prevention of Venous ThromboembolicEvents (VTE) in Subjects Undergoing an Elective, Unilateral Total Knee Replacement - N/AEUCTR2005-005179-14-PTPfizer Inc.1,255